Spruce Biosciences, Inc. Common Stock (SPRB) Stock Forecast & Price Target
Spruce Biosciences, Inc. Common Stock · NASDAQ
$41.98-1.10 (-2.55%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Spruce Biosciences, Inc. Common Stock, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $123.00 to $283.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $172.78 sits 312% above the current $41.98. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-5.31 next quarter toward $7.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Spruce Biosciences, Inc. Common Stock.
As of Jul, 9 of 9 firms rate SPRB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SPRB EPS & revenue forecast
EPS · NEXT QUARTER
$-5.31
Range $-8.04 – $-4.25 · 7 analysts · -64% YoY
Next period, 7 analysts expect Spruce Biosciences, Inc. Common Stock to earn $-5.31 a share (range $-8.04 – $-4.25), versus $-14.58 a year earlier. Full-year consensus is $-24.89, growing to $7.38 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $86.4M next year.
Top analysts covering Spruce Biosciences, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SPRB.
#1
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$150.00+257.3% to target
Overall win rate
44%
+ Follow
#2
Gregory Renza
RBC Capital · Rank #179
Hold
$0.50-98.8% to target
Overall win rate
34%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$150.00+257.3% to target
Overall win rate
37%
+ Follow
#4
Leland Gershell
Oppenheimer · Rank #254
Buy
$230.00+447.9% to target
Overall win rate
37%
+ Follow
#5
Joseph Schwartz
Leerink Partners
Buy
$120.00+185.9% to target
Coverage
—
+ Follow
SPRB stock forecast FAQ
What is SPRB's average 12-month price target?+
The 9 analysts with a live target average $172.78 for Spruce Biosciences, Inc. Common Stock over the next 12 months, ranging from a $283.00 high to a $123.00 low.
Is SPRB stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SPRB?+
The Street-high target is $283.00 (Oppenheimer), and the Street-low is $123.00 (Guggenheim). The average of all 9 active targets is $172.78.
How many Wall Street analysts cover SPRB?+
9 analysts have an active rating on Spruce Biosciences, Inc. Common Stock, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering SPRB?+
Among analysts who currently cover SPRB, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #38). Their current call is Buy with a $150.00 target.
What is Spruce Biosciences, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-5.31 per share (range $-8.04 – $-4.25) across 7 analysts. Full-year EPS is projected at $-24.89, rising to $7.38 the following year.
How much revenue is Spruce Biosciences, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $86.4M next year.
Have analysts been upgrading or downgrading SPRB lately?+
As of Jul, 9 of 9 firms rate SPRB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SPRB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
